O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+2.22%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.05B
AUM Growth
+$5.05B
(-3.3%)
Cap. Flow
-$81.2M
Cap. Flow
% of AUM
-1.61%
Top 10 Holdings %
Top 10 Hldgs %
35.6%
Holding
132
New
17
Increased
26
Reduced
29
Closed
15
Top Buys
| 1 |
Enliven Therapeutics
ELVN
|
$173M |
| 2 |
Biogen
BIIB
|
$68.6M |
| 3 |
Eli Lilly
LLY
|
$63.9M |
| 4 |
Baxter International
BAX
|
$63.4M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$60M |
Top Sells
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$117M |
| 2 |
Pfizer
PFE
|
$71.4M |
| 3 |
Natera
NTRA
|
$54M |
| 4 |
UnitedHealth
UNH
|
$49.4M |
| 5 |
89bio
ETNB
|
$46.6M |
Sector Composition
| 1 | Healthcare | 97.56% |
| 2 | Industrials | 0.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Sanofi
SNY
$122B
| – | – |
0
| – | – |
|
|
SGEN
127
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-913,812
| Closed | -$117M |
|
|
CINC
128
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| – | – |
-1,906,000
| Closed | -$23.4M |
|
|
MACK
129
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| – | – |
-73,600
| Closed | -$843K |
|